CNTB CONNECT BIOPHARMA HLDGS LTD revenue, earnings and financials
For the quarter ended June 30, 2026, CONNECT BIOPHARMA HLDGS LTD reported revenue of $2.77M (up 5666.7% from a year earlier), net income of −$17.3M and diluted EPS of −$0.27; over the last four quarters revenue was $2.95M and net income −$69.0M; for the fiscal year ended December 2025 revenue was $64.0K, down 99.8% on the year before.
CNTB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $64.0K, gross profit n/a, operating income −$58.1M, net income −$55.5M (margin -86687.5%), EPS −$1.00
- Fiscal year ended Dec 2024: revenue $26.0M, gross profit n/a, operating income −$22.5M, net income −$15.6M (margin -60.0%), EPS −$0.28
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$69.1M, net income −$62.1M (margin n/a), EPS −$1.13
CNTB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.77M (up 5666.7% year over year), net income −$17.3M, EPS −$0.27
- Quarter ended Mar 31, 2026: revenue $169K, net income −$19.4M, EPS −$0.34
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$15.1M, EPS −$0.27
- Quarter ended Sep 30, 2025: revenue $16.0K (down 98.7% year over year), net income −$17.2M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue $48.0K (down 99.8% year over year), net income −$12.9M, EPS −$0.23
- Quarter ended Mar 31, 2025: revenue $0, net income −$10.3M, EPS −$0.19
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$8.91M, EPS −$0.16
- Quarter ended Sep 30, 2024: revenue $1.22M, net income −$12.9M, EPS −$0.23
- Quarter ended Jun 30, 2024: revenue $24.1M, net income $14.8M, EPS $0.27
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.69M, EPS −$0.16
CNTB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$51.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$47.7M, share buybacks n/a
CNTB balance sheet
- Jun 30, 2026: cash $27.0M, total assets $43.5M, total liabilities $16.6M, shareholders' equity $26.9M
- Mar 31, 2026: cash $46.0M, total assets $60.1M, total liabilities $17.4M, shareholders' equity $42.6M
- Dec 31, 2025: cash $38.3M, total assets $56.1M, total liabilities $14.1M, shareholders' equity $42.0M
- Sep 30, 2025: cash $37.8M, total assets $67.4M, total liabilities $12.0M, shareholders' equity $55.4M
- Jun 30, 2025: cash $40.6M, total assets $82.7M, total liabilities $11.4M, shareholders' equity $71.3M
- Mar 31, 2025: cash $47.7M, total assets $92.7M, total liabilities $9.79M, shareholders' equity $82.9M
- Dec 31, 2024: cash $78.2M, total assets $101M, total liabilities $9.12M, shareholders' equity $92.2M
- Dec 31, 2023: cash $106M, total assets $127M, total liabilities $25.9M, shareholders' equity $101M
What is CNTB's revenue?
CONNECT BIOPHARMA HLDGS LTD reported $2.95M of revenue over its last four quarters, through June 30, 2026.
Is CNTB profitable?
No. CONNECT BIOPHARMA HLDGS LTD lost $69.0M over the last four quarters.
What is CNTB's EPS?
Diluted earnings per share over the last four quarters were −$1.19; −$0.27 in the latest quarter.